Kane Biotech (KNE) Q2 2026 earnings summary

Executive summary

• Revenue for Q2 2026 was $8,143, down from $27,997 in Q2 2025, reflecting the transition to the revyve® product line and exit from legacy operations.

• Gross profit improved to $1,444 from a gross loss of $(45,526) year-over-year, driven by early commercialization of revyve.

• Net loss widened to $(833,636) from $(348,541) due to higher operating expenses, mainly from stock option expense and absence of prior period accrual reversals.

• Focus remains on accelerating commercialization of revyve in North America, expanding distribution, and supporting adoption among clinicians.

Financial highlights

• Q2 2026 revenue: $8,143, compared to $27,997 in Q2 2025.

• Gross profit: $1,444, versus a gross loss of $(45,526) in Q2 2025.

• Operating expenses: $785,927, up from $229,930 year-over-year, mainly due to stock option expense.

• Net loss: $(833,636), compared to $(348,541) in Q2 2025.

• Cash balance at June 30, 2026: $854,729.

Outlook and guidance

• Continued focus on commercializing revyve antimicrobial wound care portfolio in Canada and the U.S.

• Ongoing expansion of distributor networks and market access.

• Advancing clinical and scientific validation, with new clinical evaluations and a real-world data registry initiated.

• Strategic review process underway to evaluate growth opportunities.